6 research outputs found

    A short-list of pairing-friendly curves resistant to Special TNFS at the 128-bit security level

    Get PDF
    https://www.iacr.org/docs/pub_2013-16.htmlThis paper is the IACR version. It can be made freely available on the homepages of authors, on their employer's institutional page, and in non-commercial archival repositories such as the Cryptology ePrint Archive, ArXiv/CoRR, HAL, etc.International audienceThere have been notable improvements in discrete logarithm computations in finite fields since 2015 and the introduction of the Tower Number Field Sieve algorithm (TNFS) for extension fields. The Special TNFS is very efficient in finite fields that are target groups of pairings on elliptic curves, where the characteristic is special (e.g.~sparse). The key sizes for pairings should be increased, and alternative pairing-friendly curves can be considered.We revisit the Special variant of TNFS for pairing-friendly curves. In this case the characteristic is given by a polynomial of moderate degree (between 4 and 38) and tiny coefficients, evaluated at an integer (a seed). We present a polynomial selection with a new practical trade-off between degree and coefficient size. As a consequence, the security of curves computed by Barbulescu, El~Mrabet and Ghammam in 2019 should be revised: we obtain a smaller estimated cost of STNFS for all curves except BLS12 and BN.To obtain TNFS-secure curves, we reconsider the Brezing--Weng generic construction of families of pairing-friendly curves and estimate the cost of our new Special TNFS algorithm for these curves. This improves on the work of Fotiadis and Konstantinou, Fotiadis and Martindale, and Barbulescu, El~Mrabet and Ghammam. We obtain a short-list of interesting families of curves that are resistant to the Special TNFS algorithm, of embedding degrees 10 to 16 for the 128-bit security level. We conclude that at the 128-bit security level, BLS-12 and Fotiadis--Konstantinou--Martindale curves with k=12k=12 over a 440 to 448-bit prime field seem to be the best choice for pairing efficiency. We also give hints at the 192-bit security level

    A short-list of pairing-friendly curves resistant to Special TNFS at the 128-bit security level

    Get PDF
    https://www.iacr.org/docs/pub_2013-16.htmlThis paper is the IACR version. It can be made freely available on the homepages of authors, on their employer's institutional page, and in non-commercial archival repositories such as the Cryptology ePrint Archive, ArXiv/CoRR, HAL, etc.International audienceThere have been notable improvements in discrete logarithm computations in finite fields since 2015 and the introduction of the Tower Number Field Sieve algorithm (TNFS) for extension fields. The Special TNFS is very efficient in finite fields that are target groups of pairings on elliptic curves, where the characteristic is special (e.g.~sparse). The key sizes for pairings should be increased, and alternative pairing-friendly curves can be considered.We revisit the Special variant of TNFS for pairing-friendly curves. In this case the characteristic is given by a polynomial of moderate degree (between 4 and 38) and tiny coefficients, evaluated at an integer (a seed). We present a polynomial selection with a new practical trade-off between degree and coefficient size. As a consequence, the security of curves computed by Barbulescu, El~Mrabet and Ghammam in 2019 should be revised: we obtain a smaller estimated cost of STNFS for all curves except BLS12 and BN.To obtain TNFS-secure curves, we reconsider the Brezing--Weng generic construction of families of pairing-friendly curves and estimate the cost of our new Special TNFS algorithm for these curves. This improves on the work of Fotiadis and Konstantinou, Fotiadis and Martindale, and Barbulescu, El~Mrabet and Ghammam. We obtain a short-list of interesting families of curves that are resistant to the Special TNFS algorithm, of embedding degrees 10 to 16 for the 128-bit security level. We conclude that at the 128-bit security level, BLS-12 and Fotiadis--Konstantinou--Martindale curves with k=12k=12 over a 440 to 448-bit prime field seem to be the best choice for pairing efficiency. We also give hints at the 192-bit security level

    Optimized and secure pairing-friendly elliptic curves suitable for one layer proof composition

    Get PDF
    International audienceA zero-knowledge proof is a method by which one can prove knowledge of general non-deterministic polynomial (NP) statements. SNARKs are in addition non-interactive, short and cheap to verify. This property makes them suitable for recursive proof composition, that is proofs attesting to the validity of other proofs. To achieve this, one moves the arithmetic operations to the exponents. Recursive proof composition has been empirically demonstrated for pairing-based SNARKs via tailored constructions of expensive pairing-friendly elliptic curves namely a pair of 753-bit MNT curves, so that one curve's order is the other curve's base field order and vice-versa. The ZEXE construction restricts to one layer proof composition and uses a pair of curves, BLS12-377 and CP6-782, which improve significantly the arithmetic on the first curve. In this work we construct a new pairing-friendly elliptic curve to be used with BLS12-377, which is STNFS-secure and fully optimized for one layer composition. We propose to name the new curve BW6-761. This work shows that it is at least five times faster to verify a composed SNARK proof on this curve compared to the previous state-of-the-art, and proposes an optimized Rust implementation that is almost thirty times faster than the one available in ZEXE library

    Edoxaban versus warfarin in patients with atrial fibrillation

    Get PDF
    Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)
    corecore